List of Tables
Summary Table A : Global Market for Cardiovascular Drugs, by Disease Area, Through 2022
Summary Table B : Global Market for Cardiovascular Drugs, by Drug Class, Through 2022
Summary Table C : Global Market for Cardiovascular Drugs, by Region, Through 2022
Table 1 : Prevalence of High Blood Pressure, Age 18+, 2015
Table 2 : List of Blockbuster Drugs, Manufacturer, 2014-2016
Table 3 : Life Expectancy at Birth, Both Sexes Combined, by Region, 1990-2030
Table 4 : Prevalence Rates for Adult Obesity, by Country, 2016
Table 5 : Prevalence Rates of Australia Obesity for Male and Female, 1995-2015
Table 6 : Cardiovascular Drugs Affected by the New Drug Price Control, Brand Name, Generic Name, Manufacturer
Table 7 : Cardiovascular Drugs Going Off-Patent, 2016-2021
Table 8 : Giapreza Snapshot
Table 9 : Uptravi Snapshot
Table 10 : Invokana Snapshot
Table 11 : Praluent Development Timeline
Table 12 : Omecamtiv Mecarbil Developmental Pipeline
Table 13 : AstraZeneca Plc. Cardiovascular Pipeline
Table 14 : Amgen Inc. Cardiovascular Pipeline
Table 15 : Pfizer Inc. Cardiovascular Pipeline
Table 16 : Sanofi Cardiovascular Pipeline
Table 17 : Novartis AG Cardiovascular Pipeline
Table 18 : Merck and Co. Inc. Cardiovascular Pipeline
Table 19 : Daiichi Sankyo Company, Ltd. Cardiovascular Pipeline
Table 20 : Bristol-Myers Squibb Company Cardiovascular Pipeline
Table 21 : Gilead Sciences Inc. Cardiovascular Pipeline
Table 22 : Indicative List of Cardiovascular Drugs Approved by U.S. FDA and Health Canada (Brand Name, Manufacturer, Indication, Approval Date, and Approving Agency), 2015-2017
Table 23 : Indicative List of Cardiovascular Drugs Approved by EMA (Brand Name, Manufacturer, Indication, and Approval Date), 2011-2016
Table 24 : Cardiovascular Drugs Approved by PMDA (Brand Name, Manufacturer, Indication, and Approval Date), 2016-2017
Table 25 : Indicative List of Cardiovascular Drugs Approved, U.S. FDA, EMA and DCGI (Generic Name, Indication, Approval Year), 2006-2011
Table 26 : Cardiovascular Drugs Approved (Brand Name, Generic Name, Approval Year, Manufacturer, and Indication), 2011-2016
Table 27 : Global Cardiovascular Drugs Market, by Disease Area, Through 2022
Table 28 : Classification of Hypertension or Blood Pressure
Table 29 : Global Hypertension Market, by Region, Through 2022
Table 30 : Recommended Cholesterol Levels
Table 31 : Global Hyperlipidemia Market, by Region, Through 2022
Table 32 : Global Thrombosis Market, by Region, Through 2022
Table 33 : Global Cardiac Failure Therapy Market, by Region, Through 2022
Table 34 : New York Heart Association Classification
Table 35 : American Heart Association Classification
Table 36 : Global Market for Other Cardiovascular Drugs, by Region, Through 2022
Table 37 : Global Alpha-Blockers Market, by Region, Through 2022
Table 38 : Global Anti-Thrombotic Market, by Region, Through 2022
Table 39 : Global Lipid Lowering Agents Market, by Region, Through 2022
Table 40 : Global Anti-Hypertensives Market, by Region, Through 2022
Table 41 : Global Anti-Arrhythmic Drugs Market, by Region, Through 2022
Table 42 : Global Anti-Arrhythmic Drug Classification, by Vaughan Williams Classification
Table 43 : Global Market for Other Cardiovascular Drugs, by Region, Through 2022
Table 44 : Global North American Cardiovascular Drugs Market, by Country, Through 2022
Table 45 : European Cardiovascular Drugs Market, by Country, Through 2022
Table 46 : Asia-Pacific Cardiovascular Drugs Market, by Country, Through 2022
Table 47 : Global Cardiovascular Companies Ranking
Table 48 : Patent Review, 2016-2017
Table 49 : Repatha Snapshot
Table 50 : Jardiance Snapshot
Table 51 : Industry-wide Collaborations
Table 52 : Amgen Net Revenue, 2015-2017
Table 53 : Amgen Inc., Marketed Products, 2016
Table 54 : Astellas Pharma Inc. Net Revenue, 2015-2017
Table 55 : Astellas Pharma Inc. Marketed Products, 2017
Table 56 : AstraZeneca PLC Net Revenue, 2014-2016
Table 57 : AstraZeneca PLC Marketed Products, 2016
Table 58 : AstraZeneca Global Cardiovascular Product Sales, 2014-2016
Table 59 : Boehringer Ingelheim GmbH Net Revenue, 2014-2016
Table 60 : Boehringer Ingelheim Marketed Products, by Indication, 2016
Table 61 : Boehringer Ingelheim GmbH Global Cardiovascular Product Sales, 2014-2016
Table 62 : Bristol-Myers Squibb Company Net Revenue, 2014-2016
Table 63 : Bristol-Myers Squibb Company Marketed Products, 2016
Table 64 : Daiichi Sankyo Company Ltd. Net Revenue, 2015-2017
Table 65 : Daiichi Sankyo Company Ltd. Marketed Products, by Indication, 2016
Table 66 : Eli Lilly and Company Net Revenue, 2014-2016
Table 67 : Eli Lilly and Company Marketed Products
Table 68 : Gilead Sciences Inc. Net Revenue, 2014-2016
Table 69 : Gilead Science Inc. Marketed Products
Table 70 : GlaxoSmithKline PLC Net Revenue, 2014-2016
Table 71 : GlaxoSmithKline PLC Marketed Products
Table 72 : Hikma Pharmaceuticals PLC Net Revenue, 2014-2016
Table 73 : Hikma Pharmaceuticals PLC Marketed Products
Table 74 : Johnson & Johnson Inc. Net Revenue, 2014-2016
Table 75 : Johnson & Johnson Inc. Marketed Products, 2016
Table 76 : Johnson & Johnson Inc. Marketed Products, by Indication, 2016
Table 77 : Merck & Co. Inc. Net Revenue, 2014-2016
Table 78 : Merck & Co. Inc. Marketed Products
Table 79 : Novartis AG Net Revenue, 2014-2016
Table 80 : Novartis AG Marketed Products by Indication, 2016
Table 81 : Pfizer Inc. Net Revenue, 2014-2016
Table 82 : Pfizer Inc. Marketed Products, by Indication, 2016
Table 83 : Sanofi Net Revenue, 2014-2016
Table 84 : Sanofi Marketed Products, by Indication, 2016
Table 85 : United Therapeutics Corp. Net Revenue, 2014-2016
Table 86 : United Therapeutics Corp. Marketed Products
Table 87 : Abbreviations Used in Cardiovascular Drug Market
List of Figures
Summary Figure A : Global Market for Cardiovascular Drugs, by Disease Area, 2016-2022
Summary Figure B : Global Market for Cardiovascular Drugs, by Drug Class, 2016-2022
Summary Figure C : Global Market for Cardiovascular Drugs, by Region, 2016-2022
Figure 1 : Noncommunicable Diseases Mortality Share, by Cause of Death, 2015
Figure 2 : Top 10 Leading Causes of Death in the World, 2015
Figure 3 : Global Population Projection, Aged 60 and Above (Per 100,000 Persons)
Figure 4 : Global Population Projection, Aged 80 and Above (Per 100,000 Persons)
Figure 5 : United States Obesity, by State, 2016
Figure 6 : U.S. Generic Drug Savings, 2005-2014
Figure 7 : Likelihood of Approval from Phase I, by Disease Area
Figure 8 : The Center for Drug Evaluation and Research, by Therapeutic Area, 2017
Figure 9 : Cardiovascular Drugs Approval Process, U.S. FDA and EMEA
Figure 10 : Approved Indications for the Most Prevalent Cardiovascular Diseases, by the U.S. FDA and Health Canada, 1980-2014
Figure 11 : China CFDA Drug Regulatory Approval Process
Figure 12 : Japan PMDA Drug Regulatory Approval Process
Figure 13 : Global Cardiovascular Disease Rates for Countries with Least Age-Standardized Mortality, 2015 (Per 100,000 Persons)
Figure 14 : Global Cardiovascular Disease Rates for Countries with Highest Age-Standardized Mortality, 2015 (Per 100,000 Persons)
Figure 15 : Global Cardiovascular Drugs Market, by Disease Area, 2016-2022
Figure 16 : Global Hypertension Market, by Region, 2016-2022
Figure 17 : Global Hyperlipidemia Market, by Region, 2016-2022
Figure 18 : Global Thrombosis Market, by Region, 2016-2022
Figure 19 : Global Cardiac Failure Therapy Market, 2016-2022
Figure 20 : Global Cardiac Failure Therapy Market, by Region, 2016-2022
Figure 21 : Global Stroke Mortality, Per 100,000
Figure 22 : Global Market for Other Cardiovascular Disease, 2016-2022
Figure 23 : Global Market for Other Cardiovascular Drugs, by Region, 2016-2022
Figure 24 : Global Alpha-Blockers Market, 2016-2022
Figure 25 : Global Alpha-Blockers Market, by Region, 2016-2022
Figure 26 : Global Anti-Thrombotic Market, 2016-2022
Figure 27 : Global Anti-Thrombotic Market, by Region, 2016-2022
Figure 28 : Global Lipid Lowering Agents Market, 2016-2022
Figure 29 : Global Lipid Lowering Agents Market, by Region, 2016-2022
Figure 30 : Global Anti-Hypertensives Market, 2016-2022
Figure 31 : Global Anti-Hypertensives Market, by Region, 2016-2022
Figure 32 : Global Anti-Arrhythmic Drugs Market, 2016-2022
Figure 33 : Global Anti-Arrhythmic Drugs Market, by Region, 2016-2022
Figure 34 : Global Market for Other Cardiovascular Drugs, by Region, 2016-2022
Figure 35 : Global Cardiovascular Deaths, by Region (Per 100,000 Persons) 2015 and 2030 (F)
Figure 36 : Global North American Cardiovascular Drugs Market, 2016-2022
Figure 37 : United States’ CVD Deaths Share, 2016
Figure 38 : United States Prevalence of Cardiovascular Disease Risk Factors, % of Adults
Figure 39 : Obese (Body Mass Index >30) and Overweight (Body Mass Index >25) Population
Figure 40 : Global North American Cardiovascular Drugs Market, by Country, 2016-2022
Figure 41 : Global North American Cardiovascular Drugs Market, by Disease Area, 2016-2022
Figure 42 : Global North American Cardiovascular Drugs Market, by Drug Class, 2016-2022
Figure 43 : Global European Cardiovascular Drugs Market, 2016-2022
Figure 44 : United Kingdom Mortality in Males, 2015
Figure 45 : United Kingdom Mortality in Females, 2015
Figure 46 : Leading Causes of Death in Italy and Percent Change, 2005-2016
Figure 47 : Spain Mortality in Women, 2014
Figure 48 : Spain Mortality in Men, 2014
Figure 49 : Leading Cause of Death in Europe, 2015
Figure 50 : Global European Cardiovascular Drugs Market, by Country, 2016-2022
Figure 51 : Global European Cardiovascular Drugs Market, by Disease Area, 2016-2022
Figure 52 : Global European Cardiovascular Drugs Market, by Drug Class, 2016-2022
Figure 53 : Asia-Pacific Population Data, by Age Group, 2016
Figure 54 : Asia-Pacific Population Data, by Age Group, 2022
Figure 55 : Asia-Pacific Cardiovascular Drugs Market, 2016-2022
Figure 56 : Singapore Causes of Death, by Cardiovascular Disease Type, 2014-2016
Figure 57 : Asia-Pacific Cardiovascular Drugs Market, by Country, 2016-2022
Figure 58 : Asia-Pacific Cardiovascular Drugs Market, by Disease Area, 2016-2022
Figure 59 : Asia-Pacific Cardiovascular Drugs Market, by Drug Class, 2016-2022
Figure 60 : Cardiovascular Mortality in Middle East and Africa Region, 2017
Figure 61 : Global Middle East and Africa Cardiovascular Drugs Market, 2016-2022
Figure 62 : Global Middle East and Africa Cardiovascular Drugs Market, by Disease Area, 2016-2022
Figure 63 : Global Middle East and Africa Cardiovascular Drugs Market, by Drug Class, 2016-2022
Figure 64 : Global South American Cardiovascular Drugs Market, 2016-2022
Figure 65 : Global South American Cardiovascular Drugs Market, by Disease Area, 2016-2022
Figure 66 : Global South American Cardiovascular Drugs Market, by Drug Class, 2016-2022
Figure 67 : Amgen Inc. Revenue Share, by Region, 2017
Figure 68 : Amgen Inc. R&D Expenditure, 2014-2016
Figure 69 : Astellas Pharma Inc. Revenue Share, by Region, 2017
Figure 70 : Astellas Pharma Inc. R&D Expenditure, 2015-2017
Figure 71 : AstraZeneca PLC Revenue Share, by Region, 2016
Figure 72 : AstraZeneca PLC Revenue Share, by Business Segment, 2016
Figure 73 : AstraZeneca PLC R&D Expenditure, 2014-2016
Figure 74 : Boehringer Ingelheim GmbH Revenue Share, by Region, 2016
Figure 75 : Boehringer Ingelheim GmbH Revenue Share, by Business Segment, 2016
Figure 76 : Boehringer Ingelheim GmbH R&D Expenditure, 2014-2016
Figure 77 : Bristol-Myers Squibb Company Revenue Share, by Region, 2016
Figure 78 : Bristol-Myers Squibb Company Revenue Share, by Business Segment, 2016
Figure 79 : Daiichi Sankyo Company Revenue Share, by Business Segment, 2016
Figure 80 : Daiichi Sankyo R&D Expenditure, 2014-2016
Figure 81 : Eli Lilly and Company Revenue Share, by Business Segment, 2016
Figure 82 : Eli Lilly and Company Revenue Share, by Region, 2016
Figure 83 : Gilead Sciences Inc. Revenue Share, by Business Segment, 2016
Figure 84 : Gilead Sciences Inc. Revenue Share, by Region, 2016
Figure 85 : GlaxoSmithKline PLC Revenue Share, by Business Segment, 2016
Figure 86 : GlaxoSmithKline PLC Revenue Share, by Region, 2016
Figure 87 : Hikma Pharmaceuticals PLC Revenue Share, by Business Segment, 2016
Figure 88 : Hikma Pharmaceuticals PLC Revenue Share, by Region, 2016
Figure 89 : Johnson and Johnson Inc. Revenue Share, by Business Segment, 2016
Figure 90 : Johnson and Johnson Inc. Revenue Share, by Region, 2016
Figure 91 : Merck & Co. Inc. Revenue Share, by Business Segment, 2016
Figure 92 : Merck & Co. Inc. Revenue Share, by Region, 2016
Figure 93 : Novartis AG Revenue Share, by Region, 2016
Figure 94 : Novartis AG Revenue Share, by Business Segment, 2016
Figure 95 : Pfizer Inc. Revenue Share, by Region, 2016
Figure 96 : Pfizer Inc. Revenue Share, by Business Segment, 2016
Figure 97 : Sanofi Revenue Share, by Region, 2016
Figure 98 : Sanofi Revenue Share, by Business Segment, 2016
Figure 99 : Sanofi R&D Expenditure, 2014-2016
